Real-World Clinical Experiences Managing Epidermolysis Bullosa with Birch Triterpenes
Hosted in Partnership with Chiesi
Dr. Joyce Teng and Dr. Emily Gorell share their real-world clinical experiences, highlighting how birch triterpenes may work to accelerate wound healing, reduce inflammation, and potentially improve quality of life for patients living with dystrophic and junctional epidermolysis bullosa (EB). The program also touches on the importance of wound preparation, potential combinatorial approaches to therapy, and holistic care approaches for these patients.
This webinar is being hosted by PeDRA and sponsored by Chiesi. PeDRA will evaluate content for suitability for its audience, but is not responsible for the creation of content, selection of speakers, or delivery of presentations. For a complete list of presenter disclosures, please click on the presenters’ photographs.
Disclosures:
- Investigator: Care within Reach, Castle Creek, EB Research Partner, Gorlin Syndrome Alliance, Innova, LeoPharm, Lifemax, Novartis, Palvella Therapeutics, Pfizer, Regeneron, Timber Pharmaceuticals, Twi Biotech
- Consultant: Abeona, AFT, Amryt (Chiesi), AUCTA, Biocryst, Bridge Bio Castle Creek, Coterie, GLG, Guide Point, Innova, Kamari, KrystalBio, LeoPharm, Lifemax, Menlo Therapeutics, Mitsubishi, NobelPharm, Novartis, Palvella Therapeutics, Pfizer, Pierre Fabre, Regeneron, Syneos, Timber Pharmaceuticals, Topicals, Twi Biotech
- Medical Advisor: BHD Foundation, EverEden Skin Care, FIRST, Gorlin Syndrome Alliance, TSC Alliance
- Loyalty: GeneReview, UpToDate, Springer Publishing
https://youtu.be/0WqU-VFoyKgDisclosures:
- Consultant: Abeona Therapeutics
- Advisory Board: Abeona Therapeutics, Chiesi USA, Krystal Biotech
- Current/prior Investigator: Chiesi USA, Abeona Therapeutics, Rheacell, TWI Biotech, Castle Creek, Phoenix Tissue Repair, Phoenicis, Krystal Biotech, Incyte, Sanofi, Pfizer
